MX2018005203A - Compuestos de pirrolo-, pirazolo-, imidazo-pirimidina y pirrolo-, pirazolo-, imidazo-piridina que inhiben cinasas 1 y 2 de interaccion con proteina cinasas activadas por mitogenos (mnk1 y mnk2). - Google Patents
Compuestos de pirrolo-, pirazolo-, imidazo-pirimidina y pirrolo-, pirazolo-, imidazo-piridina que inhiben cinasas 1 y 2 de interaccion con proteina cinasas activadas por mitogenos (mnk1 y mnk2).Info
- Publication number
- MX2018005203A MX2018005203A MX2018005203A MX2018005203A MX2018005203A MX 2018005203 A MX2018005203 A MX 2018005203A MX 2018005203 A MX2018005203 A MX 2018005203A MX 2018005203 A MX2018005203 A MX 2018005203A MX 2018005203 A MX2018005203 A MX 2018005203A
- Authority
- MX
- Mexico
- Prior art keywords
- mnk2
- pyrazolo
- pyrrolo
- imidazo
- pyrimidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
La presente invención proporciona síntesis, formulaciones farmacéuticamente aceptables y usos de los compuestos de acuerdo con la fórmula (I) o un estereoisómero, tautómero o una sal farmacéuticamente aceptable del mismo. Para los compuestos de la fórmula (I) A1, A2, A3, A4, A5, A6, A7, W1, R1, R2, R3, R4, R5a, R5b, R6, R7, R7a, R7b, R8, R8a, R8b, R9, R9a, R9b y R10 y los subíndices ``m´´ y ``n´´ son como se definen en la especificación. Los compuestos de fórmula (I) de la invención son inhibidores de Mnk y encuentran utilidad en diversas aplicaciones terapéuticas que incluyen pero que no se limitan al tratamiento de inflamación y diversos cánceres.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562247966P | 2015-10-29 | 2015-10-29 | |
PCT/US2016/059407 WO2017075412A1 (en) | 2015-10-29 | 2016-10-28 | Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018005203A true MX2018005203A (es) | 2018-07-06 |
Family
ID=57256471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018005203A MX2018005203A (es) | 2015-10-29 | 2016-10-28 | Compuestos de pirrolo-, pirazolo-, imidazo-pirimidina y pirrolo-, pirazolo-, imidazo-piridina que inhiben cinasas 1 y 2 de interaccion con proteina cinasas activadas por mitogenos (mnk1 y mnk2). |
Country Status (13)
Country | Link |
---|---|
US (2) | US20170121339A1 (es) |
EP (1) | EP3368533A1 (es) |
JP (1) | JP6888006B2 (es) |
KR (1) | KR20180070696A (es) |
CN (1) | CN108602814A (es) |
AU (1) | AU2016343980A1 (es) |
BR (1) | BR112018008711A2 (es) |
CA (1) | CA3002558A1 (es) |
EA (1) | EA034440B1 (es) |
IL (1) | IL258867A (es) |
MX (1) | MX2018005203A (es) |
SG (1) | SG11201803234TA (es) |
WO (1) | WO2017075412A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI713455B (zh) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | MnK抑制劑及其相關方法 |
MX2019009653A (es) | 2017-02-14 | 2019-12-19 | Effector Therapeutics Inc | Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos. |
JOP20180094A1 (ar) | 2017-10-18 | 2019-04-18 | Hk Inno N Corp | مركب حلقي غير متجانس كمثبط بروتين كيناز |
AU2019366947A1 (en) | 2018-10-24 | 2021-06-03 | Effector Therapeutics, Inc. | Crystalline forms of Mnk inhibitors |
CN111253397B (zh) * | 2018-11-30 | 2023-11-14 | 上海迪诺医药科技有限公司 | Mnk抑制剂 |
US20220251097A1 (en) * | 2019-08-01 | 2022-08-11 | St. Jude Childrens's Research Hospital | Molecules and methods related to treatment of uncontrolled cellular proliferation |
JP7311207B2 (ja) | 2019-11-18 | 2023-07-19 | 成都嘉葆薬銀医薬科技有限公司 | Mnk阻害剤としてのピロロトリアジン系化合物 |
IL299512A (en) * | 2020-06-30 | 2023-02-01 | 4E Therapeutics Inc | pyridine-1,5 - discussions that suppress MNK and methods of using them |
US20240092799A1 (en) * | 2020-08-20 | 2024-03-21 | Hepagene Therapeutics (HK) Limited | Mnk inhibitors |
CN117355528A (zh) | 2021-05-08 | 2024-01-05 | 成都嘉葆药银医药科技有限公司 | 吡咯并三嗪类化合物的盐型、其晶型及其制备方法 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5491144A (en) | 1991-05-30 | 1996-02-13 | Ciba-Geigy Corporation | Substituted diaminophthalimides and analogues |
US7488745B2 (en) | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
CN101309905A (zh) | 2005-08-12 | 2008-11-19 | 阿斯利康(瑞典)有限公司 | 取代的异吲哚酮及其作为代谢型谷氨酸受体增效剂的用途 |
EP1889847A1 (en) | 2006-07-10 | 2008-02-20 | DeveloGen Aktiengesellschaft | Pyrrolopyrimidines for pharmaceutical compositions |
ES2485040T3 (es) | 2007-03-16 | 2014-08-12 | The Scripps Research Institute | Inhibidores de cinasa de adhesión focal |
GB0706072D0 (en) | 2007-03-28 | 2007-05-09 | Sterix Ltd | Compound |
JP2009173629A (ja) | 2007-12-21 | 2009-08-06 | Banyu Pharmaceut Co Ltd | Rsk1阻害作用を有する新規スピロインダン誘導体 |
WO2009112445A1 (en) | 2008-03-10 | 2009-09-17 | Novartis Ag | Method of increasing cellular phosphatidyl choline by dgat1 inhibition |
TWI468402B (zh) | 2009-07-31 | 2015-01-11 | 必治妥美雅史谷比公司 | 降低β-類澱粉生成之化合物 |
US8637525B2 (en) | 2009-07-31 | 2014-01-28 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
TWI393716B (zh) | 2009-08-04 | 2013-04-21 | Merck Sharp & Dohme | 作為ixa因子抑制劑之雜環化合物 |
WO2011106168A1 (en) * | 2010-02-24 | 2011-09-01 | Dcam Pharma Inc | Purine compounds for treating autoimmune and demyelinating diseases |
AP2013006834A0 (en) | 2010-10-01 | 2013-04-30 | Bayer Ip Gmbh | Substituted N-(2-arylamino)aryl sulfonamide-containing combinations |
PT3042910T (pt) | 2010-11-30 | 2019-04-16 | Gilead Pharmasset Llc | 2'-espiro-nucleósidos para utilização na terapia da hepatite c |
US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
WO2013043192A1 (en) | 2011-09-23 | 2013-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders |
RU2705577C2 (ru) | 2011-12-30 | 2019-11-08 | Ханми Фарм. Ко., Лтд. | ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ПРОТЕИНКИНАЗ |
EP3216792B1 (en) | 2012-03-29 | 2020-05-27 | G1 Therapeutics, Inc. | Lactam kinase inhibitors |
US10280168B2 (en) | 2012-03-30 | 2019-05-07 | Agency For Science, Technology And Research | Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof |
GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
WO2013151975A1 (en) | 2012-04-02 | 2013-10-10 | Northeastern University | Compositions and methods for the inhibition of methyltransferases |
TW201412740A (zh) | 2012-09-20 | 2014-04-01 | Bayer Pharma AG | 經取代之吡咯并嘧啶胺基苯并噻唑酮 |
GB2508652A (en) | 2012-12-07 | 2014-06-11 | Agency Science Tech & Res | Heterocyclic piperazine derivatives |
EP2935304A1 (en) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
US20160287589A1 (en) | 2013-02-20 | 2016-10-06 | Bayer Pharma Aktiengesellschaft | Substituted-imidazopyridazines |
US9855268B2 (en) * | 2013-03-05 | 2018-01-02 | Merck Patent Gmbh | Triazolo[4,5-d]pyrimidine derivatives |
TW201605867A (zh) * | 2013-11-20 | 2016-02-16 | 拜耳製藥公司 | 噻吩并嘧啶 |
TWI713455B (zh) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | MnK抑制劑及其相關方法 |
WO2016172010A1 (en) * | 2015-04-20 | 2016-10-27 | Effector Therapeutics, Inc. | Inhibitors of immune checkpoint modulators for use in treating cancer and infections |
KR20180070695A (ko) | 2015-10-29 | 2018-06-26 | 이펙터 테라퓨틱스, 인크. | Mnk1 및 mnk2의 이소인돌린, 아자이소인돌린, 디히드로인데논 및 디히드로아자인데논 억제제 |
WO2017087808A1 (en) | 2015-11-20 | 2017-05-26 | Effector Therapeutics, Inc. | Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers |
EP3397774A1 (en) | 2015-12-31 | 2018-11-07 | Effector Therapeutics Inc. | Mnk biomarkers and uses thereof |
-
2016
- 2016-10-28 US US15/337,237 patent/US20170121339A1/en not_active Abandoned
- 2016-10-28 BR BR112018008711A patent/BR112018008711A2/pt not_active Application Discontinuation
- 2016-10-28 CA CA3002558A patent/CA3002558A1/en not_active Abandoned
- 2016-10-28 KR KR1020187014951A patent/KR20180070696A/ko unknown
- 2016-10-28 WO PCT/US2016/059407 patent/WO2017075412A1/en active Application Filing
- 2016-10-28 AU AU2016343980A patent/AU2016343980A1/en not_active Abandoned
- 2016-10-28 CN CN201680072179.9A patent/CN108602814A/zh active Pending
- 2016-10-28 SG SG11201803234TA patent/SG11201803234TA/en unknown
- 2016-10-28 JP JP2018521932A patent/JP6888006B2/ja active Active
- 2016-10-28 MX MX2018005203A patent/MX2018005203A/es unknown
- 2016-10-28 EP EP16794166.5A patent/EP3368533A1/en not_active Withdrawn
- 2016-10-28 EA EA201891050A patent/EA034440B1/ru not_active IP Right Cessation
-
2018
- 2018-04-23 IL IL258867A patent/IL258867A/en unknown
-
2019
- 2019-04-09 US US16/378,809 patent/US11014926B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2018531972A (ja) | 2018-11-01 |
KR20180070696A (ko) | 2018-06-26 |
BR112018008711A2 (pt) | 2018-10-30 |
CA3002558A1 (en) | 2017-05-04 |
EA201891050A1 (ru) | 2018-11-30 |
EP3368533A1 (en) | 2018-09-05 |
SG11201803234TA (en) | 2018-05-30 |
US20190330216A1 (en) | 2019-10-31 |
CN108602814A (zh) | 2018-09-28 |
JP6888006B2 (ja) | 2021-06-16 |
EA034440B1 (ru) | 2020-02-07 |
IL258867A (en) | 2018-06-28 |
US20170121339A1 (en) | 2017-05-04 |
AU2016343980A1 (en) | 2018-06-07 |
US11014926B2 (en) | 2021-05-25 |
WO2017075412A1 (en) | 2017-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018005203A (es) | Compuestos de pirrolo-, pirazolo-, imidazo-pirimidina y pirrolo-, pirazolo-, imidazo-piridina que inhiben cinasas 1 y 2 de interaccion con proteina cinasas activadas por mitogenos (mnk1 y mnk2). | |
MX2018005204A (es) | Inhibidores de isoindolina, azaisoindolina, dihidroindenona y dihidroazaindenona de cinasas 1 y 2 de interaccion con proteina cinasas activadas por mitogenos (mnk1 y mnk2). | |
PH12016500024A1 (en) | Bromodomain inhibitor | |
MY192521A (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
MX2021000781A (es) | Profarmacos de amidas de piridona utiles como moduladores de canales de sodio. | |
MX2019011530A (es) | Saxitoxinas 11,13-modificadas para el tratamiento del dolor. | |
MX2018005019A (es) | Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas. | |
MD4625C1 (ro) | Derivaţi de 5-fenoxi-3H-pirimidin-4-onă şi utilizarea acestora ca inhibitori ai transcriptazei inverse a HIV | |
WO2017087808A8 (en) | Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers | |
PH12015502004A1 (en) | Tetracyclic bromodomain inhibitors | |
PH12016500164A1 (en) | Therapeutically active compounds and their methods of use | |
PH12015501024A1 (en) | Bendamustine derivatives and methods of using same | |
MD20160053A2 (ro) | Derivaţi ai purinei 2,6-substituite şi utilizarea acestora în tratamentul tulburărilor proliferative | |
PH12016501977A1 (en) | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES | |
MX2019011743A (es) | Derivados de tiocarbamato como inhibidores de a2a y metodos para su uso en el tratamiento de canceres. | |
MX2016007440A (es) | Inhibidores del bromodominio. | |
MY179605A (en) | Use of benzimidazole-proline derivatives | |
MY196276A (en) | Isoindole Compounds | |
PH12018500378B1 (en) | Novel annelated phenoxyacetamides | |
GEP20186934B (en) | Quinolizinone derivatives as pi3k inhibitors | |
MX2016003522A (es) | Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa. | |
PH12017501369A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
PH12016501997B1 (en) | Cycloalkyl-linked diheterocycle derivatives | |
PH12020500542A1 (en) | Dopamine-b-hydroxylase inhibitors | |
ZA202203106B (en) | Thiazole carboxamide compounds and use thereof for the treatment of mycobacterial infections |